Thank you, MJ. Our GAAP book value at December 31, 2022, was $269.3 million or $6.19 per basic share compared to $282.5 million or $7.33 per share at September 30, 2022 and $430.5 million or $8.80 per share as of December 31, 2021. This reflects the initial Starboard transaction that was completed in the fourth quarter. Subsequent to the end of this year, we completed a rights offering, raising net proceeds of $79 million to Acacia. Inclusive of that offering, our book value is approximately $5.95 per share, and our capital base stood at 348.4 million, including $366.9 million in cash. The quarterly results reflected several nonrecurring items, including foreign and embedded derivative related charges, severance for former employees, including former CEO, legal and professional fees related to the Starboard recap. As an important note, we expect that interest income, combined with profits from our IP business and Printronix to cover Acacia's fixed costs. A key part of this is the elimination of approximately $6 million in annualized G&A costs. Let me now turn to the fourth quarter results. Revenues for the fourth quarter of 2022 were $13.1 million, compared to $63.3 million a year ago. Breaking that down. First, Printronix contributed $10.6 million in revenue in the quarter, compared to $12 million in the prior year quarter. Second, our intellectual property business generated $2.5 million in revenue related to patent assertion, compared to $51.3 million in the fourth quarter last year. This is a reflection of the uneven nature of revenue timing in this business. General and administrative expenses were $15.9 million, compared to $12.7 million in the fourth quarter last year due to an increase business development and personnel expenses related to the company's transaction organization, cost for the Starboard recap, as well as nonrecurring severance costs. I would note on a go-forward basis, we have eliminated approximately one-third of our annualized general and administrative costs. Operating loss was $14.5 million in the quarter, compared to operating income of $31.3 million a year ago. Printronix contributed $0.1 million in operating income. Realized and unrealized gains on securities totaled $13.4 million in the quarter, a reflection of the increase in share price of our security positions over the last three months. We realized $10.6 million in realized gains from the sales of securities during the quarter, primarily from the sales of the shares in our life sciences portfolio, which we continue to bring to realization. This includes fully exiting our position in Oxford Nanopore. We sold approximately 7.9 million shares of Oxford Nanopore in the fourth quarter. Also, we received a $27 million payment related to our share in Biomet in the quarter, bringing our total milestone income to date to $30 million. Our carrying value of Biomet is approximately $19 million, net of non-controlling interest. So we have already realized a solid return on this position, irrespective of future commercialization activity and any return from selling this position in the future. Our GAAP net loss was $18.4 million or $0.55 per diluted share compared to GAAP net income of $204.2 million or $0.45 per diluted share in the fourth quarter of last year. Once again, the net loss reflects several nonrecurring items, including; first, $10.9 million in realized gains and $2.5 million in unrealized gains related to the increase in share price of certain holdings, partially offset by the reversal of unrealized gains previously recorded for shares sold during the quarter for realized gains. Second, non-cash expense of $21.5 million related to the change in fair value of the Starboard warrants and embedded derivative liabilities, due to the increase in Acacia's stock price during the quarter, and the reduction in the exercise price of the Series B $5.25 warrant for the foregone time value of the Series B warrants and the preferred stock. Third, $9.2 million in charges related to severance, legal and other professional fees associated with the recapitalization. At the beginning of 2021, our NOL plus capital loss carryforwards stood at $286 million. And since that time, we have effectively sheltered all of our gains. We will continue to evaluate the most efficient ways to maximize this asset. As of December 31, 2022, our realized gain had reduced our NOLs to approximately $64 million for the full year. Total revenues were $59.2 million compared to $88 million last year. Printronix generated $39.7 million in revenues for the year. The intellectual property business generated $19.5 million in licensing and other revenues compared to $76 million last year. General and administrative expenses were $52.7 million compared to $35.7 million last year due to the inclusion of a full year of Printronix operating expenses, increased parent business development expenses and other one-time charges. Our operating loss was $40.1 million compared to an operating income of $14.5 million last year. Printronix contributed $1.1 million in operating income. GAAP net loss was $125.1 million, or $3.13 per diluted share compared to GAAP net income of $149.2 million, or $1.91 per diluted share last year. Net income included $125.3 million in realized gains offset by $263.7 million in unrealized losses related to the decline in share price of certain holdings as well as the reversal of unrealized gains previously recorded for shares sold during the year for realized gains. We also recognized non-cash income of $13.1 million related to the change in fair value of the Starboard warrants and embedded derivative liabilities, due to the decline in Acacia stock price during the year. Last year, Acacia recognized $202 million in realized and unrealized gains in the value of the life sciences portfolio, primarily related to the IPO of Oxford Nanopore in September 2021. Turning to the balance sheet. Cash and equity securities at fair value totaled $349.4 million at December 31, 2022 compared to $670.7 million at December 31, 2021. During 2022, Acacia repaid $120 million in principal amount of senior secured notes held by Starboard and repurchased $51 million in Acacia shares. Equity securities without readily determinable fair value totaled $5.8 million at December 31, 2022, which amount was unchanged from December 31, 2021. Investment securities representing equity method investments net of non-controlling interests, totaled $19.9 million at December 31, 2022 and December 31, 2021. All milestone payments earned by MalinJ1 through its interest in Viamet have been received. Acacia owns 64% of MalinJ1. Total indebtedness, which represents the senior secured notes issued to Starboard, was $60.5 million at December 31, 2022. More detail on these results have been made available in the press release issued this morning and in our annual report on Form 10-K, which we will file with the SEC later this week. Our GAAP book value as discussed today, includes the impact of all warrant and embedded derivative liabilities on our balance sheet, which, in turn, reflects the impact of the increase in the company's share price over time, as these liabilities would be extinguished upon exercise or expiration of these warrants and convertible preferred stock. We think it's more useful to consider our book value should all of these instruments be converted. The Starboard transaction should convert or extinguish these transactions with the final step being the exercise of our Series B warrants in July of this year. The press release issued earlier today includes a detailed breakdown of our capital structure and explanations of how our capital structure will change as a result of the ongoing steps of our process with Starboard. In summary, upon completion of the recapitalization transactions with Starboard, $9.3 million of cash was received, net of the early termination settlement for the exercise of the remaining Series A warrants and 5 million shares of common stock were issued. Starboard has purchased 15 million new shares in the recently completed rights offering, at $5.25 per share, for total proceeds of $78.8 million in the first quarter of 2023. $35 million in face value Series A preferred stock will be eliminated and 9.6 million shares of common stock would be issued in June of 2023, following Acacia's Annual Meeting of Stockholders. $60.5 million of liabilities attributable to the senior secured notes would be eliminated, and Starboard would invest an additional $55 million in cash related to the Series B warrant exercise, and 31.3 million shares of common stock would be issued by July 2023. $101.6 million of warrant and embedded derivative liabilities attributable to the Series B warrants and Series A preferred stock would be eliminated by July of 2023. Acacia would pay Starboard a total of $66 million as consideration for early exercise of the Series B warrants, and convertible preferred stock by July 2023. And Acacia will incur transaction costs associated with the negotiation and consummation of the recapitalization transactions. The expected impact of the completion of the recapitalization transaction from December 31, 2022, would be an incremental $246.4 million in book value, and an incremental $56.2 million of shares outstanding. Assuming such completion, pro forma book value would be $489.9 million and diluted shares outstanding would be $104.3 million, resulting in pro forma book value per share of $4.70 at December 31, 2022. Over the next few months, the transaction agreed to with Starboard will result in the streamlining of our capital structure and the strengthening of our capital base. This should be complete by the time we report our second quarter results in mid-August. We continue to believe that cash per share is an important metric for measuring our progress. As of December 31, 2022, our cash per share stood at $6.62. On a pro forma basis, assuming completion of all phases of the Starboard transaction, our cash per share would be approximately $3.54. With that, we'd be pleased to take your questions.